Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS-II: Neoadjuvant Regimens for Gastric Cancer
NCT02931890Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2017
- Primary completion
- Apr 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, capecitabine, paclitaxel oral solution, carboplatin in gastric cancer (GC), sponsored by Netherlands Cancer Institute. Started Dec 2017; status: active, not recruiting.
02
Drugs
docetaxeloxaliplatincapecitabinepaclitaxel oral solutioncarboplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02931890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931890.